A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread (NICAM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01395121|
Recruitment Status : Completed
First Posted : July 15, 2011
Last Update Posted : June 8, 2017
|Condition or disease||Intervention/treatment||Phase|
|Mucosal Lentiginous Melanoma Acral Lentiginous Malignant Melanoma||Drug: nilotinib||Phase 2|
NICAM has a two step consent process. Patients diagnosed with advanced acral or mucosal melanoma first consent for study registration and undergo screening tests including testing samples of melanoma tissue for the c-KIT mutation.
Following confirmation of the c-KIT mutation, patients are asked to consent to study entry with continuation of screening. Eligible patients then enter the study and commence taking nilotinib tablets twice a day for as long as clinical benefit is maintained.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||29 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Trial of Nilotinib in the Treatment of Patients With c-KIT Mutated Advanced Acral and Mucosal Melanoma|
|Actual Study Start Date :||December 2009|
|Actual Primary Completion Date :||December 12, 2016|
|Actual Study Completion Date :||December 12, 2016|
nilotinib 400mgs oral tablets
nilotinib 400 mgs orally twice daily until disease progression or withdrawal from treatment
Other Name: Tasigna
- Proportion of participants with the c-KIT mutation who remain progression free at 6 months. [ Time Frame: 6 months ]Progression free survival times will be measured from the date of enrolment into the treatment phase until the first date (following start of treatment) of either death or confirmed progressive disease according to RECIST.
- toxicity of treatment [ Time Frame: evaluated every 4 weeks whilst the patient is on treatment (on average estimated to be between 4 and 52 weeks) ]Treatment related toxicity will be assessed at each clinic visit approximately every 4 weeks whilst the patient continues on study treatment. Study treatment will continue until the patient relapses or is withdrawn from study therapy (on average estimated to be between 4 and 52 weeks).
- response at 12 weeks [ Time Frame: tumours measured at 12 weeks from start of treatment ]Lesions must be measured and or evaluated at 12 weeks in accordance with the Response evaluation criteria in solid tumours (RECIST)
- overall survival [ Time Frame: Expected to be 6 - 12 months (Measured from commencement of treatment until time of death) ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01395121
|Royal Marsden NHS Foundation Trust|
|London, United Kingdom, SW3 6JJ|
|Principal Investigator:||James Larkin, MA BM BCh MRCP PhD||Royal Marsden NHS Foundation|